Alcobra: Does The Pre-Data Selloff Imply A Failed Phase 3? Roth Capital Comments


In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Alcobra (NASDAQ:ADHD) with a $40 price target. The report comes in light of the recent pull-back that was driven by speculation of negative phase 3 data.

Chattopadhyay wrote, “Potentially flawed comparisons between metadoxine (which positively impacts cognitive function) with its structural analog pyridoxine (which has no impact on cognitive function) has been highlighted as a potential driver of phase 3 failure. Despite the negative sentiment on the phase 3 outcome, we expect MDX to deliver a clinically meaningful benefit in the ADHD-PI subgroup, but not the ADHD-C subgroup.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -4.4% and a 21.1% success rate. Chattopadhyay has a -30.5% average return when recommending ADHD, and is ranked #3036 out of 3314 analysts.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts